Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2024-09-13 Board/Management Inform…
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically details the departure of a senior officer (Chief Development Officer) due to a contemplated merger and mentions severance benefits. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3399 characters, which is consistent with a typical 8-K filing for management changes.
2024-09-13 English
Regulatory Filings 2024
Regulatory Filings
2024-08-27 English
424B3
Merger & Acquisition Classification · 100% confidence The document is a detailed filing pursuant to Rule 424(b)(3) related to a proposed merger between Reneo Pharmaceuticals, Inc. and OnKure, Inc. It includes extensive information about the merger agreement, stockholder voting, share exchange ratios, and related transactions. It also references a proxy statement/prospectus and a special meeting of stockholders to approve the merger. The content is focused on merger transaction details and solicitation of shareholder votes, typical of merger-related filings. The document is not a full annual or quarterly report, audit report, earnings release, or other financial report. It is a merger-related disclosure and solicitation document, which aligns with the category for Merger & Acquisition filings (MA). The presence of the proxy statement/prospectus and detailed merger terms confirms this classification.
2024-08-26 English
S-4/A
M&A Activity Classification · 100% confidence The document is a Form S-4/A Registration Statement Amendment No. 3 filed with the SEC, dated August 26, 2024. It details a proposed merger transaction between Reneo Pharmaceuticals, Inc. and OnKure, Inc., including terms of the merger, stock exchange ratios, equity plans, PIPE investments, and conditions to closing. The document is a comprehensive filing related to a merger transaction, including detailed merger agreement terms and shareholder meeting information. This type of filing is specifically related to merger and acquisition activity and is not a proxy statement, earnings release, or other report type. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR). The document length (15,000 characters) and content confirm it is the actual merger filing, not just an announcement or proxy solicitation.
2024-08-26 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter from Reneo Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-4. Form S-4 is used for securities registration related to mergers, acquisitions, or exchange offers. The letter is a formal request related to the regulatory process of a merger or acquisition filing, not the filing itself or a report of financial results. The document is short (1467 characters) and is a correspondence related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory communication that does not contain financial data or detailed report content itself.
2024-08-23 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Reneo Pharmaceuticals, Inc. to the SEC responding to comments on Amendment No. 1 to a Registration Statement on Form S-4 filed on July 29, 2024. The letter discusses revisions to the Form S-4, which is a registration statement used for securities offerings, often related to mergers or acquisitions. The content includes detailed responses to SEC staff comments about financial disclosures, business descriptions, and accounting treatments related to a merger. The document is not the registration statement itself but a correspondence addressing SEC comments on the filing. It is not a full financial report, earnings release, or other report types but a regulatory correspondence related to a filing. Therefore, the best classification is Regulatory Filings (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2024-08-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.